In CAST therapy, stroma-targeting immunoconjugates bound to the stroma generate a scaffold, from which controlled release of cytotoxic drugs occurred and afterward diffused throughout the tumor tissue to damage both tumor cells and tumor vessels. The gene discussed is CAST; the disease is neoplasm.